|
US4647580A
(en)
|
1985-07-18 |
1987-03-03 |
Syntex (U.S.A.) Inc. |
Treatment of Alzheimer's disease
|
|
US5043345A
(en)
|
1989-02-22 |
1991-08-27 |
Novo Nordisk A/S |
Piperidine compounds and their preparation and use
|
|
US5852029A
(en)
|
1990-04-10 |
1998-12-22 |
Israel Institute For Biological Research |
Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
|
|
US5480651A
(en)
|
1992-03-16 |
1996-01-02 |
Regents Of The University Of California |
Composition and method for treating nicotine craving in smoking cessation
|
|
PT734259E
(pt)
*
|
1993-08-19 |
2002-11-29 |
Novo Nordisk As |
Utilizacao de derivados de piperidina para o tratamento da esquizofrenia
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2000515213A
(ja)
|
1996-01-19 |
2000-11-14 |
ラファエル、ピーター、ロバート |
三サイクルエンジン
|
|
DE19612504C2
(de)
|
1996-03-29 |
2003-10-23 |
Boehringer Ingelheim Kg |
Neue Wirkstoffkompositionen
|
|
GB9612710D0
(en)
|
1996-06-18 |
1996-08-21 |
Pfizer Ltd |
Method of treatment
|
|
EP0821958A3
(en)
|
1996-08-01 |
1998-07-08 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
|
|
EP0821959A3
(en)
|
1996-08-01 |
1998-09-16 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
|
|
EP0821954A1
(en)
|
1996-08-01 |
1998-02-04 |
Eli Lilly And Company |
Method for treating mental retardation
|
|
EP0821956A1
(en)
|
1996-08-01 |
1998-02-04 |
Eli Lilly And Company |
Method for treating disruptive behavior disorders
|
|
EP0821955B1
(en)
|
1996-08-01 |
2002-02-20 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder
|
|
EP0821957A3
(en)
|
1996-08-01 |
1998-04-22 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
|
|
WO1998030243A1
(en)
|
1997-01-08 |
1998-07-16 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
KR20010072784A
(ko)
|
1998-08-18 |
2001-07-31 |
지. 카파트 |
무스카린성 작용제 및 길항제
|
|
WO2001062236A2
(en)
|
2000-02-24 |
2001-08-30 |
Pharmacia & Upjohn Company |
New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
WO2002003684A2
(en)
|
2000-06-30 |
2002-01-10 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
|
CA2432543A1
(en)
|
2000-12-22 |
2002-07-04 |
Takeda Chemical Industries, Ltd. |
Combination drugs
|
|
US6862890B2
(en)
*
|
2001-01-30 |
2005-03-08 |
Board Of Regents, University Of Texas System |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20040224012A1
(en)
|
2001-10-05 |
2004-11-11 |
Pichit Suvanprakorn |
Topical application and methods for administration of active agents using liposome macro-beads
|
|
WO2003030818A2
(en)
|
2001-10-05 |
2003-04-17 |
Pichit Suvanprakorn |
Active agents using liposome beads
|
|
PL207038B1
(pl)
*
|
2002-01-25 |
2010-10-29 |
Theravance |
Podstawione pochodne kwasu fenylooctowego, związek pośredni, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie
|
|
WO2004060347A2
(en)
|
2002-09-03 |
2004-07-22 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
JP4584706B2
(ja)
|
2002-05-03 |
2010-11-24 |
イスラエル インスティチュート フォー バイオロジカル リサーチ |
中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US20050250767A1
(en)
|
2003-01-23 |
2005-11-10 |
Weiner David M |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
US20050085463A1
(en)
|
2003-01-23 |
2005-04-21 |
Weiner David M. |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
GB0307860D0
(en)
|
2003-04-04 |
2003-05-14 |
Novartis Ag |
Organic compounds
|
|
JP5547865B2
(ja)
|
2003-10-29 |
2014-07-16 |
ワイス・エルエルシー |
アプリンドルおよびその誘導体を含む持続放出型医薬組成物
|
|
DE602004030931D1
(enExample)
|
2003-11-04 |
2011-02-17 |
Supernus Pharmaceuticals Inc |
|
|
US7763609B2
(en)
|
2003-12-15 |
2010-07-27 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
|
BRPI0417749A
(pt)
|
2003-12-22 |
2007-04-10 |
Acadia Pharm Inc |
composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
|
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
|
ES2257152B1
(es)
|
2004-05-31 |
2007-07-01 |
Laboratorios Almirall S.A. |
Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
|
|
JP2008504372A
(ja)
|
2004-06-18 |
2008-02-14 |
ニューロケム （インターナショナル） リミティッド |
β−アミロイド関連疾患の治療のための治療用製剤
|
|
GB0428170D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Mono and Combination Therapy
|
|
GB0428180D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Combination therapy
|
|
WO2006086698A2
(en)
|
2005-02-11 |
2006-08-17 |
Stephen Wills |
Treating microvasculature diseases with acetyl cholinesterase inhibitors
|
|
JP4732769B2
(ja)
|
2005-03-04 |
2011-07-27 |
富士フイルム株式会社 |
内視鏡装置
|
|
TW200800959A
(en)
|
2005-06-10 |
2008-01-01 |
Wyeth Corp |
Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
|
|
US7759353B2
(en)
|
2005-06-14 |
2010-07-20 |
Schering Corporation |
Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment
|
|
US7390816B2
(en)
|
2005-06-21 |
2008-06-24 |
Bridge Pharma, Inc. |
Methods for treating urinary incontinence in patients suffering from memory disorders
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
RU2435610C2
(ru)
|
2005-09-02 |
2011-12-10 |
Теравида, Инк. |
Терапия для лечения заболевания
|
|
US8158152B2
(en)
|
2005-11-18 |
2012-04-17 |
Scidose Llc |
Lyophilization process and products obtained thereby
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
TW200811105A
(en)
|
2006-04-25 |
2008-03-01 |
Theravance Inc |
Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
AU2007247231B2
(en)
|
2006-05-04 |
2012-05-31 |
Solvay Pharmaceuticals B.V. |
Muscarinic agonists to treat impulse control disorders
|
|
US7905852B2
(en)
|
2006-05-16 |
2011-03-15 |
Barbara Jennings-Spring |
Skin-contacting-adhesive free dressing
|
|
US8097633B2
(en)
|
2006-11-15 |
2012-01-17 |
Rich Steven A |
Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
|
|
WO2008076287A2
(en)
|
2006-12-13 |
2008-06-26 |
Tuel Stephen M |
Methods of making pharmaceutical components for customized drug products
|
|
GB0702385D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702416D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702457D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination 666
|
|
GB0702456D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination
|
|
GB0703999D0
(en)
|
2007-03-01 |
2007-04-11 |
Astrazeneca Ab |
New combination 667
|
|
EP2141992A1
(en)
|
2007-03-29 |
2010-01-13 |
Merck & Co., Inc. |
Combination therapy for the treatment-of lower urinary tract symptoms
|
|
CL2008001970A1
(es)
*
|
2007-07-03 |
2009-03-27 |
Synthon Bv |
Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
|
|
US20100329996A1
(en)
|
2007-09-12 |
2010-12-30 |
Glaxo Group Limited |
Novel Combination of Therapeutic Agents
|
|
WO2009037503A2
(en)
|
2007-09-18 |
2009-03-26 |
Astrazeneca Ab |
New combination - 012 for the treatment of respiratory diseases
|
|
NO2200610T3
(enExample)
|
2007-09-21 |
2018-06-09 |
|
|
|
TWI454288B
(zh)
|
2008-01-25 |
2014-10-01 |
Gruenenthal Chemie |
藥物劑型
|
|
EP4088717A1
(en)
|
2008-03-27 |
2022-11-16 |
Chase Pharmaceuticals Corporation |
Use and composition for treating dementia
|
|
WO2009132239A2
(en)
|
2008-04-24 |
2009-10-29 |
Trustees Of Boston University |
A network biology approach for identifying targets for combination therapies
|
|
GB0822077D0
(en)
|
2008-12-03 |
2009-01-07 |
Minster Res Ltd |
Novel treatments
|
|
WO2010102218A1
(en)
|
2009-03-05 |
2010-09-10 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
US10265311B2
(en)
*
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
ES2742728T3
(es)
|
2009-07-22 |
2020-02-17 |
PureTech Health LLC |
Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
|
|
WO2011085406A1
(en)
|
2010-01-11 |
2011-07-14 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
GB2479213B
(en)
|
2010-04-01 |
2013-07-10 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
|
WO2012033956A1
(en)
|
2010-09-08 |
2012-03-15 |
Mithridion, Inc. |
Cognition enhancing compounds and compositions, methods of making, and methods of treating
|
|
AU2012253669A1
(en)
*
|
2011-05-10 |
2013-11-28 |
Theravida, Inc. |
Combinations of trospium and salivary stimulants for the treatment of overactive bladder
|
|
CA2835293C
(en)
|
2011-06-08 |
2020-08-18 |
Sti Pharma, Llc |
Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
AU2013312749B2
(en)
|
2012-09-05 |
2018-01-18 |
Chase Pharmaceuticals Corporation |
Anticholinergic neuroprotective composition and methods
|
|
US10307409B2
(en)
|
2015-03-06 |
2019-06-04 |
Chase Pharmaceuticals Corporation |
Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
|
|
EP3265466A4
(en)
|
2015-03-06 |
2018-12-26 |
Chase Pharmaceuticals Corporation |
Peripheral-anticholinergic muscarinic agonist combination
|
|
EP3265067A4
(en)
|
2015-03-06 |
2018-09-12 |
Chase Pharmaceuticals Corporation |
Oxybutynin-xanomeline transdermal therapeutic system combinations
|
|
JP6566254B2
(ja)
|
2015-08-21 |
2019-08-28 |
セイコープレシジョン株式会社 |
フォーカルプレーンシャッタおよび光学機器
|
|
UA125747C2
(uk)
*
|
2015-09-01 |
2022-06-01 |
Фьост Вейв Байо, Інк. |
Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
|
|
CA2996719A1
(en)
|
2015-09-11 |
2017-03-16 |
Chase Pharmaceuticals Corporation |
Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
|
|
CL2018000559A1
(es)
|
2015-10-14 |
2018-08-17 |
First Wave Bio Inc |
Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales
|
|
KR102600541B1
(ko)
|
2016-01-20 |
2023-11-08 |
테라비다, 인코포레이티드 |
다한증을 치료하기 위한 방법 및 조성물
|
|
WO2017147104A1
(en)
|
2016-02-24 |
2017-08-31 |
Chase Pharmaceuticals Corporation |
Muscarinic m2-antagonist combinations
|
|
JP7197472B2
(ja)
|
2017-05-19 |
2022-12-27 |
武田薬品工業株式会社 |
スクリーニング方法
|
|
MX2020010993A
(es)
|
2018-04-19 |
2020-12-09 |
Ucar Health Gmbh |
Propiedades antimicrobianas para superficies, aire, textiles, pinturas, plasticos, silicona, madera, polietileno, metales y sus derivados.
|
|
PT3856182T
(pt)
|
2018-09-28 |
2026-03-10 |
Karuna Therapeutics Inc |
Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
|
|
US20210145804A1
(en)
|
2019-11-18 |
2021-05-20 |
Karuna Therapeutics, Inc. |
Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
|
|
JP2023503056A
(ja)
|
2019-11-18 |
2023-01-26 |
カルナ セラピューティックス，インコーポレイテッド |
ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
|
|
AU2022226157A1
(en)
|
2021-02-24 |
2023-09-14 |
Karuna Therapeutics, Inc. |
Methods for treating disorders ameliorated by muscarinic receptor activation
|
|
US20220370454A1
(en)
|
2021-05-18 |
2022-11-24 |
Karuna Therapeutics, Inc. |
Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics
|
|
US20250228832A1
(en)
|
2022-04-07 |
2025-07-17 |
Karuna Therapeutics, Inc. |
Methods for treating disorders ameliorated by muscarinic receptor activation
|